SCHEMBL5651224

SCHEMBL5651224

COCCN(C[C@@H]1C[C@H]1C)c1cc(-c2nnc([C@@](C)(Cc3ccccc3)NC(=O)O)o2)cc(N(C)S(C)(=O)=O)n1

nearest known ligand 0.49

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 19/20 0.49
BACE2 Q9Y5Z0 1/20 0.39
LIPG Q9Y5X9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651218 1.00 BACE1 (0.49) BACE1BACE2LIPG
SCHEMBL4946005 0.91 BACE1 (0.43) BACE1BACE2
SCHEMBL2023415 0.91 BACE1 (0.43) BACE1BACE2
SCHEMBL5650931 0.91 BACE1 (0.43) BACE1BACE2
SCHEMBL5650929 0.91 BACE1 (0.43) BACE1BACE2
SCHEMBL5649022 0.90 BACE1 (0.48) BACE1BACE2
SCHEMBL5649025 0.90 BACE1 (0.48) BACE1BACE2
SCHEMBL2019551 0.88 BACE1 (0.50) BACE1BACE2
SCHEMBL5651205 0.88 BACE1 (0.50) BACE1BACE2
SCHEMBL2019553 0.88 BACE1 (0.50) BACE1BACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394837-B2 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme, Corp. (US) 2013-03-12 US disclosed
EP-1817311-B1 2,3,4,6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2012-10-17 EP disclosed
US-20070293497-A1 2,3,4,6-Substituted Pyridyl Derivative Compounds Useful As Beta-Secretase Inhibitors For The Treatment Of Alzheimer's Disease MERCK SHARP & DOHME LLC 2007-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293497-A1 2,3,4,6-Substituted Pyridyl Derivative Compounds Useful As Beta-Secretase Inhibitors For The Treatment Of Alzheimer's Disease BACE1, BACE2, PSEN2 BACE1 1/4885BACE2 2/4885LIPG 2099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.